Myeloma News and Research

RSS

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

26 Jul 2024

Study highlights infection as major post-CAR-T therapy challenge

In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study published in Blood Advances.

25 Jul 2024

Simple blood test may predict CAR-T therapy success in multiple myeloma

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research from Weill Cornell Medicine, NewYork-Presbyterian, Columbia University and Icahn School of Medicine at Mount Sinai.

24 Jul 2024

Proteomic signatures enhance risk prediction for both common and rare diseases

Researchers have developed sparse prediction models combining plasma proteins and clinical data to predict the 10-year risk of 218 diseases. The study, involving over 41,000 participants, highlights the enhanced predictive power of proteomic signatures.

24 Jul 2024

Research shows the ability of proteins to predict onset of many diverse diseases

Research on thousands of proteins measured from a drop of blood demonstrates the ability of proteins to predict the onset of many diverse diseases.

22 Jul 2024

NYU Langone Health earns No. 1 spot in neurology and neurosurgery for the third straight year

NYU Langone Health has reaffirmed its position as the nation's top hospital for neurology and neurosurgery, securing the No. 1 ranking for the third straight year in U.S. News & World Report's annual assessment of leading hospitals.

16 Jul 2024

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy treatments.

11 Jul 2024

GLP-1 drugs found to lower cancer risk in diabetes patients

Research finds that GLP-1 receptor agonists significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetes patients compared to insulins, but show varied results against metformin.

8 Jul 2024

Early detection of aggressive multiple myeloma through molecular analysis

Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable.

1 Jul 2024

FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

25 Jun 2024

Case study sheds light on CAR-T therapy-related secondary cancers

A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial cancer provides rare but important insights intended to offer helpful guidance for oncologists and pathologists about the clinical presentation and pathologic features involved in a CAR-T related second cancer.

13 Jun 2024

Understanding cancer progression through noninvasive two-color "diffuse in vivo flow cytometry"

In the relentless fight against cancer, a new technology promises to shed light on how we track and understand the spread of this disease within the body.

7 Jun 2024

UC San Diego Health launches personalized immunotherapy for metastatic melanoma

UC San Diego Health is the first hospital system in the region to offer a new immunotherapy treatment for metastatic melanoma.

4 Jun 2024

New antibody therapy shows promise in combating kidney transplant rejection

Antibody-mediated rejection (AMR) is one of the most common causes of kidney transplant failure. To date, however, no treatment has proven effective in combating this complication in the long term.

27 May 2024

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent.

24 May 2024

Proteins in the blood could warn people of cancer more than seven years before it is diagnosed

Researchers from the UK investigated associations between 1,463 plasma proteins and 19 cancers, using observational and genetic approaches in participants of the UK Biobank.

17 May 2024

Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring

Rapid Novor Inc., a global leader in mass spectrometry (MS)-based antibody protein sequencing, today announced that the first patient has been enrolled in a new clinical study titled 'Clinical evaluation of EasyM™ for disease response analysis in newly diagnosed MM patients (NDMM)'.

From Rapid Novor Inc 16 May 2024

Questions about childhood weight can help identify increased mortality risk in adults with obesity

Being asked whether you considered yourself a normal weight, plumper or thinner as a child when attending a doctor's appointment as an adult might appear like a very strange question to ask, but new research being presented at this year's European Congress on Obesity in Venice, Italy (12-15 May) suggests that such questions can help identify increased mortality risk in adults living with obesity.

13 May 2024

Exposed to agent orange at US bases, veterans face cancer without VA compensation

As a young GI at Fort Ord in Monterey County, California, Dean Osborn spent much of his time in the oceanside woodlands, training on soil and guzzling water from streams and aquifers now known to be contaminated with cancer-causing pollutants.

29 Apr 2024

Study finds rise in volumes and survival after hematopoietic cell transplants among racial/ethnic minorities

The volume of hematopoietic cell transplants rose among all racial/ethnic groups, but grew faster among African Americans and Hispanics compared with Non-Hispanic white individuals, mirroring changes in population growth rates.

25 Apr 2024